MaxCyte, Inc. (NASDAQ:MXCT) Shares Bought by Gagnon Securities LLC

Gagnon Securities LLC raised its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 234.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 197,326 shares of the company's stock after purchasing an additional 138,257 shares during the period. Gagnon Securities LLC owned 0.19% of MaxCyte worth $821,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of MXCT. Intech Investment Management LLC acquired a new position in shares of MaxCyte in the 3rd quarter valued at $51,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of MaxCyte by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company's stock worth $79,000 after purchasing an additional 7,930 shares during the last quarter. Verition Fund Management LLC increased its position in shares of MaxCyte by 39.5% during the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company's stock worth $83,000 after purchasing an additional 6,045 shares in the last quarter. Creative Planning lifted its holdings in shares of MaxCyte by 33.6% in the 3rd quarter. Creative Planning now owns 28,652 shares of the company's stock valued at $111,000 after purchasing an additional 7,212 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of MaxCyte by 84.5% in the 3rd quarter. SG Americas Securities LLC now owns 37,969 shares of the company's stock valued at $148,000 after purchasing an additional 17,385 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Stock Up 1.3 %

NASDAQ:MXCT traded up $0.06 during mid-day trading on Wednesday, reaching $4.56. 133,686 shares of the stock were exchanged, compared to its average volume of 625,277. MaxCyte, Inc. has a 1 year low of $3.16 and a 1 year high of $5.26. The company has a 50 day simple moving average of $4.31 and a 200-day simple moving average of $4.08. The stock has a market capitalization of $481.93 million, a P/E ratio of -13.40 and a beta of 1.30.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The firm had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. During the same quarter in the prior year, the firm earned ($0.11) EPS. As a group, research analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.